VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Pregnancy                                          │ Pregnancy                                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Positive HBs Ag                                    │ Positive HBs Ag                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Informed consent obtained with information sheet   │ Informed consent obtained with information sheet   │     100 │
│ given and explained and the consent form signed by │ given and explained and the consent form signed by │         │
│ the participant of the project investigator at the │ the participant of the project investigator at the │         │
│ latest the day of the inclusion                    │ latest the day of the inclusion                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women refusing HBs Ag test                         │ Women refusing HBs Ag test                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HIV co-infection                                   │ HIV co-infection                                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HCV co-infection                                   │ HCV co-infection                                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HBV treatment ongoing at the day of inclusion      │ HBV treatment ongoing at the day of inclusion      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe gravidic disease present at inclusion       │ Severe gravidic disease present at inclusion       │     100 │
│ involving life threatening to the mother and/or    │ involving life threatening to the mother and/or    │         │
│ the child                                          │ the child                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of pre-existing fetal anomalies           │ Evidence of pre-existing fetal anomalies           │     100 │
│ incompatible with the child's life                 │ incompatible with the child's life                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Imminent child's birth defined as cervix           │ Imminent child's birth defined as cervix           │     100 │
│ dilatation up to 7 centimeters                     │ dilatation up to 7 centimeters                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intention to deliver in a maternity not linked to  │ Intention to deliver in a maternity not linked to  │     100 │
│ the study                                          │ the study                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any concomitant medical condition that, according  │ Any concomitant medical condition that, according  │     100 │
│ to the clinical site investigator would            │ to the clinical site investigator would            │         │
│ contraindicate participation in the study          │ contraindicate participation in the study          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrent participation in any other clinical     │ Concurrent participation in any other clinical     │     100 │
│ trial without written agreement of the two study   │ trial without written agreement of the two study   │         │
│ teams                                              │ teams                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Creatinine clearance \< 30 mL/min                  │ Creatinine clearance < 30 mL/min                   │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \>= 18 years old the day of inclusion              │ >= 18 years old the day of inclusion               │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                 │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 50 Years │ HBV treatment ongoing at the day of inclusion │      33 │
├───────────────────────────────────┼───────────────────────────────────────────────┼─────────┤
│ Must be FEMALE                    │ Positive HBs Ag                               │      34 │
├───────────────────────────────────┼───────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ HBV treatment ongoing at the day of inclusion │      36 │
╘═══════════════════════════════════╧═══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 96
Average Levenshtein Ratio of individual lines: 88.88888888888889
OverAll Ratio: 92.44444444444444
